Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
S-268024
- Development stage
- Unknown
- Lead developer
- Shionogi
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Administration
- Intranasal
01
Overview
S-268024 is an intranasal COVID-19 vaccine candidate developed by Shionogi & Co., Ltd. Unlike traditional intramuscular vaccines, S-268024 is designed to be administered via the nasal passage to induce mucosal immunity (IgA) in the upper respiratory tract, which is the primary entry point for the SARS-CoV-2 virus, in addition to systemic immunity (IgG). It is a recombinant protein subunit vaccine that targets the spike protein of the virus. By stimulating local immunity in the nose and throat, it aims to not only prevent severe disease but also potentially reduce viral transmission more effectively than systemic vaccines.
- Brand names
- Nuvaxovid
- Other names
- Novavax COVID-19 Vaccine, AdjuvantedSARS-CoV-2 rSSARS-CoV2 rSSARS-CoV 2 rS
02
Targets
SARS-CoV-2 spike
Beyond the preview
Go deeper on S-268024.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on S-268024.